Pharmako Biotechnologies’ reveals its PlexoZome Curcumin has positive effects on A549 human lung adenocarcinoma cells, according to a newly published study. The company emphasizes that the findings may be a foundation to develop a curcumin-based nanoformulation as a therapy for NSCLC (non-small cell lung cancer).
